JAGSNPHARM vs KILITCH: Stock Comparison
JAGSONPAL PHARMACEUTICALS is the larger company by market capitalisation. JAGSONPAL PHARMACEUTICALS shows a lower P/E, a higher ROE and a higher dividend yield, while KILITCH shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
JAGSNPHARM leads 9; KILITCH leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | JAGSNPHARM | KILITCH |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | JAGSNPHARM | KILITCH |
|---|---|---|
| Live Price | ₹242.06 | ₹196.99 |
| Day Change | -0.4% | -4.15% |
| Volume | 96,227 | 1.36 L |
| 52-Week High | ₹264.5 | ₹439 |
| 52-Week Low | ₹155 | ₹117.25 |
| Distance from 52W High | -8.48% | -55.13% |
Valuation
| Metric | JAGSNPHARM | KILITCH |
|---|---|---|
| Market Cap | ₹1,593 Cr | ₹630 Cr |
| P/E Ratio | 0x | 20.22x |
| P/B Ratio | 0x | 2.17x |
| EPS | ₹2 | ₹1.45 |
| Book Value | ₹41.95 | ₹79.19 |
| Dividend Yield | 1.03% | 0% |
Growth
| Metric | JAGSNPHARM | KILITCH |
|---|---|---|
| Revenue Growth (TTM YoY) | 9.6% | 46.3% |
| EPS Growth (TTM YoY) | 23.8% | 26.5% |
| Qtr Sales Growth | 28.08% | -8.84% |
| Qtr Profit Growth | 50.52% | 156.81% |
Profitability & Leverage
| Metric | JAGSNPHARM | KILITCH |
|---|---|---|
| ROE | 15.6% | 9.73% |
| ROCE | 16.4% | 8.32% |
| Net Margin | 15% | 12.81% |
| Operating Margin | 20.38% | 23.33% |
| Debt to Equity | 0x | 0.27x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | JAGSNPHARM | KILITCH |
|---|---|---|
| Promoter Holding | 25.55%▲ 0.43 pp | 63.77% |
| FII Holding | 2.3%▼ 0.14 pp | 0.12%▲ 0.12 pp |
| DII Holding | 0.62%▲ 0.4 pp | 0% |
| Public Holding | 28.03%▼ 1.42 pp | 36.11%▼ 0.11 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JAGSONPAL PHARMACEUTICALS and KILITCH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.